MASIMO CORP (MASI) rated Outperform with price target $29 by Boenning & Scattergood
MASIMO CORP (NASDAQ: MASI) rated
Outperform with price target $29 by Boenning & Scattergood.
Masimo develops innovative monitoring technologies that significantly improve patient care -- helping solve `unsolvable` problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry's ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of `Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.`
Our equity research team concentrates on companies that aren’t widely covered in sectors such as water distribution/equipment/technology, financial services, business services, aerospace & defense technology, medical technology and retail.